Pdia3 Defines a Novel Subset of Adipose Macrophages Exacerbating the Development of Obesity and Metabolic Disorders

Pdia3 Defines a Novel Subset of Adipose Macrophages Exacerbating the Development of Obesity and Metabolic Disorders

Novel Subpopulation of Adipose Tissue Macrophages IMAMs and Their Role in Obesity and Metabolic Disorders Background Obesity is an increasingly severe health issue worldwide, often accompanied by a state of chronic low-grade inflammation. This condition is driven by the infiltration and dysfunction of immune cells within adipose tissue and other me...

The Therapeutic Potential of Ferroterminator1 in Treating Metabolic Dysfunction-Associated Steatohepatitis

Comprehensive Clinical and Preclinical Studies Reveal the Therapeutic Potential of Ferroterminator1 (FOT1) for Metabolic-Associated Fatty Liver Disease (MAFLD) Background: Research Needs on MAFLD and Iron Overload Issues Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a common chroni...

Integrated Electrophysiological and Genomic Profiles of Single Cells Reveal Spiking Tumor Cells in Human Glioma

Integration of Electrophysiological and Genomic Analysis Reveals Tumor Cells Capable of Generating Action Potentials in Human Gliomas Background and Research Objectives Gliomas are the most common malignant tumors in the central nervous system, with approximately 20,000 new cases annually. These tumors include two subtypes: isocitrate dehydrogenase...

Cross-Tissue Human Fibroblast Atlas Reveals Myofibroblast Subtypes with Distinct Roles in Immune Modulation

Cross-Organ Human Fibroblast Atlas Reveals Unique Roles of Different Myofibroblast Subtypes in Immune Regulation Research Background and Motivation Fibroblasts play critical roles in maintaining tissue homeostasis, inflammatory responses, fibrosis, and cancer progression. In recent years, the diversity of fibroblasts in the tumor microenvironment (...

Fibrotic Response to Anti-CSF-1R Therapy Potentiates Glioblastoma Recurrence

Fibrotic Response to Anti-CSF-1R Therapy Potentiates Glioblastoma Recurrence

Fibrotic Response Induced by Anti-CSF-1R Treatment Promotes Glioblastoma Recurrence Background Introduction Glioblastoma (GBM) is a highly aggressive and malignant primary tumor of the central nervous system. Although current standard treatments include surgical resection, Temozolomide chemotherapy, and fractionated radiotherapy, the median surviva...

Fusobacterium nucleatum Facilitates Anti-PD-1 Therapy in Microsatellite Stable Colorectal Cancer

Fusobacterium nucleatum Promotes Anti-PD-1 Therapy in Microsatellite-Stable Colorectal Cancer Background Introduction With the rise of immune checkpoint blockade (ICB) therapy, a new dawn has emerged in cancer treatment. However, despite the approval of PD-1 targeting drugs (e.g., Pembrolizumab) for certain types of colorectal cancer (CRC) patients...

A Prospective Study of Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: The Keystone-001 Trial

Background and Research Motivation Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive cancer, especially in locally advanced stages. Traditional neoadjuvant chemoradiotherapy (NCRT) is the standard treatment method for this type of cancer. Despite its significant therapeutic effects, local recurrence and distant metastasis rates remai...

The Role of Combined Anti-PD-1 and Anti-CTLA-4 Therapy in Clonal Responses

Role of Combined Anti-PD-1 and Anti-CTLA-4 Therapy in Melanoma Immune Response Background Immune checkpoint inhibitors have made significant progress in clinical oncology, especially anti-PD-1 (anti-programmed death protein 1) and anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated antigen 4) therapies, which have been proven to induce long-term re...

Circulating Tumor DNA-Based Stratification Strategy for Chemotherapy Plus PD-1 Inhibitor in Advanced Non-Small-Cell Lung Cancer

Exploration of a Chemotherapy and PD-1 Inhibitor Personalized Stratification Strategy Based on Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Background and Significance of the Study Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths globally. In the treatment of advanced NSCLC, the combination of immune ...

Distinct Clinical Outcomes and Biological Features of Specific KRAS Mutants in Human Pancreatic Cancer

Clinical Outcomes and Biological Characteristics Study Report for Pancreatic Cancer Patients with KRAS Mutations Research Background and Objective Pancreatic Ductal Adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. Only about 20% of PDAC patients are eligible for resection surgery, thus the five-year sur...